Liquid Biopsy Developer Huidu Medical Closes Series B-1 for Precise Biomarker
Huidu Medical closed the Series B-1 fundraising of over CNY 100 million to bankroll global business expansion, team building and product development. The investment is led by Bayland Capital, participated by serial investor HLC and Sangel Capital.
Founded in 2015, the Shanghai-based startup has developed a new-generation ‘RNA + DNA’ based liquid biopsy technology and algorithmic model and smart medical data platform. It has two international standard labs in Shanghai and New York, recognized by Clinical Laboratory Improvement Amendments (CLIA) and College of American Pathologists (CAP).